Advances in Bioinformatics
Volume 2010 (2010), Article ID 178069, 6 pages
doi:10.1155/2010/178069
Research Article

Algorithmic Assessment of Vaccine-Induced Selective Pressure and Its Implications on Future Vaccine Candidates

Mones S. Abu-Asab,1 Majid Laassri,2 and Hakima Amri3

1Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
2Laboratory of Methods Development, Center for Biologics Evaluation and Research, Food and Drug Administration, Rockville, MD 20852, USA
3Department of Physiology and Biophysics, School of Medicine, Georgetown University, Washington, DC 20007, USA

Received 21 August 2009; Accepted 4 November 2009

Academic Editor: Wojciech Makalowski

Copyright © 2010 Mones S. Abu-Asab et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. J. McElrath, S. C. De Rosa, Z. Moodie, et al., “HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis,” The Lancet, vol. 372, no. 9653, pp. 1894–1905, 2008. View at Publisher · View at Google Scholar
  2. E. Check Hayden, “HIV: the next shot,” Nature, vol. 454, no. 7204, pp. 565–569, 2008. View at Publisher · View at Google Scholar · View at PubMed
  3. M. Abu-Asab, M. Chaouchi, and H. Amri, “Evolutionary medicine: a meaningful connection between omics, disease, and treatment,” Proteomics—Clinical Applications, vol. 2, no. 2, pp. 122–134, 2008. View at Publisher · View at Google Scholar · View at PubMed
  4. P. A. Goloboff and D. Pol, “Parsimony and bayesian phylogenetics,” in Parsimony, Phylogeny, and Genomics, V. A. Albert, Ed., Oxford University Press, Oxford, UK, 2005.
  5. D. Paraskevis, E. Magiorkinis, G. Magiorkinis, et al., “Increasing prevalence of HIV-1 subtype a in Greece: estimating epidemic history and origin,” Journal of Infectious Diseases, vol. 196, no. 8, pp. 1167–1176, 2007. View at Publisher · View at Google Scholar · View at PubMed
  6. W.-H. Lee and W.-K. Sung, “RB-finder: an improved distance-based sliding window method to detect recombination breakpoints,” Journal of Computational Biology, vol. 15, no. 7, pp. 881–898, 2008. View at Publisher · View at Google Scholar · View at PubMed
  7. J. W. Boslego, E. C. Tramont, R. C. Chung, et al., “Efficacy trial of a parenteral gonococcal pilus vaccine in men,” Vaccine, vol. 9, no. 3, pp. 154–162, 1991.
  8. C. C. Brinton, J. Bryan, J.-A. Dillon, et al., “Uses of pili in gonorrhea control: role of bacterial pili in disease, purification and properties of gonococcal pili, and progress in the development of a gonococcal pilus vaccine for gonorrhea,” in Immunobiology of Neisseria Gonorrhoeae, G. E. Brooks, E. C. Gotschlich, K. K. Holmes, W. D. Sawyer, and F. E. Young, Eds., pp. 155–178, American Society for Microbiology, Washington, DC, USA, 1978.
  9. D. S. Kellogg Jr., I. R. Cohen, L. C. Norins, A. L. Schroeter, and G. Reising, “Neisseria gonorrhoeae. II. Colonial variation and pathogenicity during 35 months in vitro,” Journal of Bacteriology, vol. 96, no. 3, pp. 596–605, 1968.
  10. J. Swanson, K. Robbins, O. Barrera, et al., “Gonococcal pilin variants in experimental gonorrhea,” Journal of Experimental Medicine, vol. 165, no. 5, pp. 1344–1357, 1987.
  11. M. S. Rohrer, M. P. Lazio, and H. S. Seifert, “A real-time semi-quantitative RT-PCR assay demonstrates that the pilE sequence dictates the frequency and characteristics of pilin antigenic variation in Neisseria gonorrhoeae,” Nucleic Acids Research, vol. 33, no. 10, pp. 3363–3371, 2005. View at Publisher · View at Google Scholar · View at PubMed
  12. E. V. Sechman, M. S. Rohrer, and H. S. Seifert, “A genetic screen identifies genes and sites involved in pilin antigenic variation in Neisseria gonorrhoeae,” Molecular Microbiology, vol. 57, no. 2, pp. 468–483, 2005. View at Publisher · View at Google Scholar · View at PubMed
  13. A. K. Criss, K. A. Kline, and H. S. Seifert, “The frequency and rate of pilin antigenic variation in Neisseria gonorrhoeae,” Molecular Microbiology, vol. 58, no. 2, pp. 510–519, 2005. View at Publisher · View at Google Scholar · View at PubMed
  14. R. Haas and T. F. Meyer, “The repertoire of silent pilus genes in Neisseria gonorrhoeae: evidence for gene conversion,” Cell, vol. 44, no. 1, pp. 107–115, 1986.
  15. T. F. Meyer and J. P. M. Van Putten, “Genetic mechanisms and biological implications of phase variation in pathogenic neisseriae,” Clinical Microbiology Reviews, vol. 2, supplement, pp. S139–S145, 1989.
  16. T. F. Meyer, E. Billyard, R. Haas, S. Storzbach, and M. So, “Pilus genes of Neisseria gonorrheae: chromosomal organization and DNA sequence,” Proceedings of the National Academy of Sciences of the United States of America, vol. 81, no. 19, pp. 6110–6114, 1984.
  17. A. C. F. Perry, I. J. Nicolson, and J. R. Saunders, “Structural analysis of the pilE region of Neisseria gonorrhoeae P9,” Gene, vol. 60, no. 1, pp. 85–92, 1987.
  18. K. B. Nicohas and H. B. Nicholad, “GeneDoc: a tool for editing and annotating multiple sequence alignments,” 1997.
  19. J. Felsenstein, “PHYLIP: phylogeny inference package (version 3.2),” Cladistics, vol. 5, pp. 164–166, 1989.
  20. C. C. Brinton, S. W. Wood, A. Brown, et al., “The development of a Neisserial pilus vaccine for gonorrhea and meningitis,” in Seminars in Infectious Disease: Bacterial Vaccines, J. B. Robbins, J. C. Hill, and J. C. Sadoff, Eds., vol. 4, pp. 140–159, Thieme-Stratton, New York, NY, USA, 1982.
  21. J. Swanson, S. J. Kraus, and E. C. Gotschlich, “Studies on gonococcus infection. I. Pili and zones of adhesion: their relation to gonococcal growth patterns,” Journal of Experimental Medicine, vol. 134, no. 4, pp. 886–906, 1971.
  22. B. Nagy, H. W. Moon, R. E. Isaacson, C. C. To, and C. C. Brinton, “Immunization of suckling pigs against enteric enterotoxigenic Escherichia coli infection by vaccinating dams with purified pili,” Infection and Immunity, vol. 21, no. 1, pp. 269–274, 1978.
  23. M. Siegel, D. Olsen, C. Critchlow, and T. M. Buchanan, “Gonococcal pili: safety and immunogenicity in humans and antibody function in vitro,” Journal of Infectious Diseases, vol. 145, no. 3, pp. 300–310, 1982.
  24. S. C. Johnson, R. C. Y. Chung, C. D. Deal, et al., “Human immunization with Pgh 3-2 gonococcal pilus results in cross-reactive antibody to the cyanogen bromide fragment-2 of pilin,” Journal of Infectious Diseases, vol. 163, no. 1, pp. 128–134, 1991.
  25. National Center for Health Statistics (U.S.), Health, United States, 2006, Department of Health and Human Services, Centers for Disease Control and Prevention, Atlanta, Ga, USA; Public Health Service, Washington, DC, USA, 2006.
  26. H. S. Seifert, “Questions about gonococcal pilus phase- and antigenic variation,” Molecular Microbiology, vol. 21, no. 3, pp. 433–440, 1996.